C4 Therapeutics, Inc. 8K

C4 Therapeutics reported Q2 2026 financial results, detailed progress and timelines for its cemsidomide multiple myeloma trials, announced a new Roche collaboration and ATM equity proceeds, and projected sufficient cash to fund operations through 2028.

On August 11, 2026, C4 Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided operational updates, highlighting continued advancement of its lead IKZF1/3 degrader cemsidomide through the Phase 2 MOMENTUM trial and multiple Phase 1b combination studies, disclosure of additional supportive clinical data presented at the EHA 2026 Congress, and upcoming data and conference milestones through 2027. The company also announced a new collaboration with Roche on degrader-antibody conjugates, for which it received a $20 million upfront payment in May 2026, and raised approximately $33.5 million in the quarter via its at-the-market equity program, contributing to a cash, cash equivalents and marketable securities balance of $300.4 million as of June 30, 2026 and an expected cash runway through the end of 2028, despite continuing to operate at a net loss. Overall, the 8-K emphasizes the company’s progress in its multiple myeloma clinical program, strengthened liquidity, and key upcoming clinical and business milestones.

Filing Facts

CIK

1662579

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-055490

Alert Tier

6